Use este identificador para citar ou linkar para este item: https://repositorio.ufjf.br/jspui/handle/ufjf/8366
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
T-cell large granular lymphocytic leukemia.pdf145.69 kBAdobe PDFThumbnail
Visualizar/Abrir
Tipo: Artigo de Periódico
Título: T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
Autor(es): Costa, Renata Oliveira
Bellesso, Marcelo
Chamone, Dalton Alencar Fischer
Ruiz, Milton Artur
Hallack Neto, Abrahão Elias
Aldred, Vera Lucia
Pereira, Juliana
Resumo: -
Abstract: OBJECTIVES: The aim of this retrospective study was to investigate the results of T-cell large granular lymphocytic leukemia treatment with fludarabine by assessing the complete hematologic response, the complete molecular response, progression-free survival, and overall survival. METHODS: We evaluated the records of six patients with T-cell large granular lymphocytic leukemia who were treated with fludarabine as a first-, second-, or third-line therapy, at a dose of 40 mg/m2, for three to five days per month and 6 to 8 cycles. RESULTS: Of the six patients investigated with T-cell large granular lymphocytic leukemia who were treated with fludarabine, five (83.3%) were female, and their median age was 36.5 years (range 18 to 73). The median lymphocyte level was 3.4x109/L (0.5 to 8.9). All patients exhibited a monoclonal T-cell receptor gamma gene rearrangement at diagnosis. Two (33.3%) patients received fludarabine as first-line treatment, two (33.3%) for refractory disease, one (16.6%) for relapsed disease after the suspension of methotrexate treatment dueto liver toxicity, and one (16.6%) due to dyspesia. A complete hematologic response was achieved in all cases, and a complete molecular response was achieved in five out six cases (83.3%). During a mean follow-up period of 12 months, both the progression-free survival and overall survival rates were 100%. CONCLUSION: T-cell large granular lymphocytic leukemia demonstrated a high rate of complete hematologic and molecular response to fludarabine, with excellent compliance and tolerability rates. To confirm our results in this rare disease, we believe that fludarabine should be tested in clinical trials as a first-line treatment for T-cell large granular lymphocytic leukemia.
Palavras-chave: Fludarabine
Treatment
Large Granular Lymphocyte Leukemia
CNPq: -
Idioma: eng
País: Brasil
Editor: -
Sigla da Instituição: -
Tipo de Acesso: Acesso Aberto
DOI: http://dx.doi.org/10.6061/clinics/2012(07)07
URI: https://repositorio.ufjf.br/jspui/handle/ufjf/8366
Data do documento: Jul-2012
Aparece nas coleções:Artigos de Periódicos



Os itens no repositório estão protegidos por licenças Creative Commons, com todos os direitos reservados, salvo quando é indicado o contrário.